European Medicines Agency to Move to Amsterdam

A coin toss decides the agency’s post-Brexit home once it departs from London.

| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

AmsterdamISTOCK, KARP85The European Medicines Agency (EMA), an organization that regulates drugs sold in the European Union for human and animal use, determined today (November 20) it will move from London to Amsterdam. The agency, which EU Observer reports employs 890 people, is making the move because of Britain’s decision to leave the E.U. in 2019. It has been based in London since 1995, the BBC reports.

Cities across Europe bid to be the new site for the EMA, which “promises to make its new host into a hub for Europe's medical industry,” the BBC notes. After three rounds of voting among EU ministers, Milan and Amsterdam were tied for the most votes, so the winner was decided by a coin toss. A vote on the new location for the European Banking Agency, also headquartered in London, is expected later today.

“The relocation of the E.M.A. away from London will be a bitter pill to swallow,” says Rory Palmer, a spokesperson for the UK Labour Party’s lawmakers in the European Parliament, in a statement to the New York Times. “Our economy will suffer. Our health sector will suffer. Our successful pharmaceutical industry ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • Shawna Williams

    Shawna was an editor at The Scientist from 2017 through 2022. She holds a bachelor's degree in biochemistry from Colorado College and a graduate certificate and science communication from the University of California, Santa Cruz.
Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Photo of a researcher overseeing large scale production processes in a laboratory.

Scaling Lentiviral Vector Manufacturing for Optimal Productivity

Thermo Fisher Logo
Collage-style urban graphic of wastewater surveillance and treatment

Putting Pathogens to the Test with Wastewater Surveillance

An illustration of an mRNA molecule in front of a multicolored background.

Generating High-Quality mRNA for In Vivo Delivery with lipid nanoparticles

Thermo Fisher Logo
Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide